Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Bo Wen
Observed name:
Wen, Bo
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
University of Michigan,
Bristol-Myers Squibb (United States),
Beijing University of Chemical Technology
Observed institutions:
Shanghai Medical College of Fudan University,
Fudan University,
University of Michigan,
Southwest Medical University,
Bristol-Myers Squibb (United States),
New York University,
Beijing University of Chemical Technology
show all 7
ORCID:
0000-0002-8337-220X
Observed ORCID:
0000-0002-8337-220X
OpenAlex ID:
A5090127271
Deep learning integrates histopathology and proteogenomics at a pan-cancer level
2023
·
Joshua M. Wang
, Runyu Hong
, et al.
·
Cell Reports Medicine
·
59
PDF
Molecular profiling of core immune-escape genes highlights LCK as an immune-related prognostic biomarker in melanoma
2022
·
Fang Wang
, Anfu Zheng
, et al.
·
Frontiers in Immunology
·
38
Dual targeting of PI3Kγ and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic cancer
2026
·
Chengyi Li
, Fang Ke
, et al.
·
Nature Cancer
·
4
Discovery of SMD-6346: A Potent, Selective, and Orally Active SMARCA2 Degrader for Targeting SMARCA4-Deficient Human Cancers
2026
·
Lingying Leng
, Liyue Huang
, et al.
·
Journal of Medicinal Chemistry
·
3
PDF
Discovery of SD-965 as a Potent, Selective, and Efficacious STAT3 PROTAC Degrader
2026
·
Dimin Wu
, Haibin Zhou
, et al.
·
Journal of Medicinal Chemistry
·
3
Pan-cancer Myc modulator that targets Myc-α-tubulin interaction to drive selective mitotic catastrophe
2025
·
Jessica Teitel
, Margaret Farah
, et al.
·
Scientific Reports
·
3
PDF
Discovery of Highly Efficacious CRBN-Based KRAS Degraders Targeting Cancers with KRAS G12D and G12V Mutations
2026
·
Changwei Wang
, Prithwish Ghosh
, et al.
·
Journal of Medicinal Chemistry
·
1
Discovery of SD-2301 as a Highly Potent and Selective PROTAC STAT3 Degrader Capable of Achieving Complete Tumor Regression with Single Administration
2026
·
Ranjan Kumar Acharyya
, Longchuan Bai
, et al.
·
Journal of Medicinal Chemistry
·
1
PDF
Characterization of Cancer Hallmark Enhancer RNA Uncovers Novel Strategies for Precision Oncology
2026
·
Yongfeng Fu
, Yunzhe Wang
, et al.
·
Genomics Proteomics & Bioinformatics
·
1
Abstract 5151: Design and synthesis of highly efficacious CRBN-based pan-KRAS degraders targeting cancers with KRAS G12D, G12V and G12C mutations
2026
·
Changwei Wang
, Prithwish Ghosh
, et al.
·
Cancer Research
·
1
Absorption, distribution, metabolism, and excretion of the BMS-986365 ligand-directed degrader diastereomers, R,R-[14C]BMS-986409 and R,S-[14C]BMS-986410, following oral administration in combination with an intravenous microtracer in healthy male participants
2026
·
Robert L. Walsky
, Shih-Hsun Cheng
, et al.
·
Drug Metabolism and Disposition
Proteogenomic analysis of pediatric and AYA high-grade glioma reveals age-dependent biology, female-male differences, and kinase targets
2026
·
Nicole L. Tignor
, Mateusz Koptyra
, et al.
·
Cell Reports Medicine
Metalloimmunotherapies: metal-driven regulatory networks in the immune microenvironment
2026
·
Bo Wen
, Yifei Wu
, et al.
·
Frontiers in Immunology
PDF
bacNeo: A Computational Toolkit for Identifying Bacteria‐Derived Neoantigens in Human Cancers
2026
·
Yunzhe Wang
, Li Yuan
, et al.
·
iMetaMed
Show more works
View as search
Works count:
17
Citation count:
114
H-index:
3
I10-index:
2
Year
Topic
Type